These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
158 related articles for article (PubMed ID: 27560702)
1. Pulmonary pharmacodynamics of an anti-GM-CSFRα antibody enables therapeutic dosing that limits exposure in the lung. Campbell J; Nys J; Eghobamien L; Cohen ES; Robinson MJ; Sleeman MA MAbs; 2016 Oct; 8(7):1398-1406. PubMed ID: 27560702 [TBL] [Abstract][Full Text] [Related]
2. Granulocyte macrophage colony-stimulating factor receptor α expression and its targeting in antigen-induced arthritis and inflammation. Cook AD; Louis C; Robinson MJ; Saleh R; Sleeman MA; Hamilton JA Arthritis Res Ther; 2016 Dec; 18(1):287. PubMed ID: 27908288 [TBL] [Abstract][Full Text] [Related]
3. Preclinical characterisation of the GM-CSF receptor as a therapeutic target in rheumatoid arthritis. Greven DE; Cohen ES; Gerlag DM; Campbell J; Woods J; Davis N; van Nieuwenhuijze A; Lewis A; Heasmen S; McCourt M; Corkill D; Dodd A; Elvin J; Statache G; Wicks IP; Anderson IK; Nash A; Sleeman MA; Tak PP Ann Rheum Dis; 2015 Oct; 74(10):1924-30. PubMed ID: 24936585 [TBL] [Abstract][Full Text] [Related]
4. Nonclinical safety of mavrilimumab, an anti-GMCSF receptor alpha monoclonal antibody, in cynomolgus monkeys: relevance for human safety. Ryan PC; Sleeman MA; Rebelatto M; Wang B; Lu H; Chen X; Wu CY; Hinrichs MJ; Roskos L; Towers H; McKeever K; Dixit R Toxicol Appl Pharmacol; 2014 Sep; 279(2):230-9. PubMed ID: 24937321 [TBL] [Abstract][Full Text] [Related]
5. Chronic pharmacological antagonism of the GM-CSF receptor in mice does not replicate the pulmonary alveolar proteinosis phenotype but does alter lung surfactant turnover. Corkill DJ; Hunt AN; Hinrichs MJ; White N; Rebelatto M; Roskos L; Nys J; Scott A; Robinson MJ; Ryan P; Postle AD; Sleeman MA Clin Sci (Lond); 2021 Nov; 135(22):2559-2573. PubMed ID: 34778899 [TBL] [Abstract][Full Text] [Related]
14. Pulmonary alveolar proteinosis is a disease of decreased availability of GM-CSF rather than an intrinsic cellular defect. Thomassen MJ; Yi T; Raychaudhuri B; Malur A; Kavuru MS Clin Immunol; 2000 May; 95(2):85-92. PubMed ID: 10779401 [TBL] [Abstract][Full Text] [Related]
15. Mechanistic modeling of antigen sink effect for mavrilimumab following intravenous administration in patients with rheumatoid arthritis. Wang B; Lau YY; Liang M; Vainshtein I; Zusmanovich M; Lu H; Magrini F; Sleeman M; Roskos L J Clin Pharmacol; 2012 Aug; 52(8):1150-61. PubMed ID: 21947370 [TBL] [Abstract][Full Text] [Related]
16. The VICM biomarker is released from activated macrophages and inhibited by anti-GM-CSFRα-mAb treatment in rheumatoid arthritis patients. Mortensen JH; Guo X; De Los Reyes M; Dziegiel MH; Karsdal MA; Bay-Jensen AC; White WI Clin Exp Rheumatol; 2019; 37(1):73-80. PubMed ID: 30418117 [TBL] [Abstract][Full Text] [Related]